{"id":"05523","slug":"small-molecule-cb1-inhibitors--05523","source":{"id":"05523","dataset":"techtransfer","title":"Small-Molecule CB1 Inhibitors for Obesity, Metabolic Disease, and Liver Disorders","description_":"<p>This invention is a family of small-molecule compounds that inhibit cannabinoid receptor type 1 (CB1) activity when administered to a mammal. It offers a single chemical platform for treating obesity, diabetes, dyslipidaemia, atherosclerosis, and liver disorders such as NASH.</p><p><h2>Description</h2>CB1 is a receptor on cells that helps regulate appetite, metabolism, and related disease processes. The invention is a defined class of small molecules, described by a core chemical structure (Formula I) with a set of allowed chemical groups at defined positions, that reduce CB1 activity when given to a mammal. \r<br>\r<br>The method claims cover administering an effective amount of one of these compounds, or a pharmaceutically acceptable salt (a common drug-grade form of the compound), to inhibit CB1 activity. The claims also cover using this inhibition to treat obesity, fear, metabolic-related disorders, diabetes, dyslipidaemia, atherosclerosis, and liver disorders. The liver disorders named are fatty liver disease, nonalcoholic steatohepatitis (NASH), cirrhosis, and liver cancer.</p><p><h2>Applications</h2>- Anti-obesity and weight-management therapeutics\r<br>- Treatment of diabetes and other metabolic-related disorders\r<br>- Therapies for dyslipidaemia and atherosclerosis\r<br>- Treatment of liver disorders, including fatty liver disease, NASH, cirrhosis, and liver cancer\r<br>- Treatment of fear-related conditions</p><p><h2>Advantages</h2>- Defined small-molecule chemical class with a specific structural formula and named lead compounds\r<br>- Flexible scaffold, with a broad range of permitted substituents supporting further optimization\r<br>- One mechanism (CB1 inhibition) applicable to several related conditions: obesity, diabetes, dyslipidaemia, atherosclerosis, and liver disease\r<br>- Claimed use across the spectrum of liver disease, from fatty liver to NASH, cirrhosis, and liver cancer\r<br>- Deliverable as the free compound or a pharmaceutically acceptable salt</p><p><h2>Invention Readiness</h2>In vitro</p><p><h2>IP Status</h2>US12,758,564</p><p></p>","tags":[],"file_number":"05523","collections":[{"key":517,"name":"Cardiometabolic"}],"meta_description":"Small-molecule CB1 inhibitors targeting obesity, metabolic disorders, and liver diseases (NASH, cirrhosis, cancer).","image_url":"","apriori_judge_output":"{\"scores\":{\"novelty\":4.0,\"potential_impact\":4.0,\"readiness\":2.0,\"scalability\":3.0,\"timeliness\":2.0},\"weighted_score\":3.2,\"risks\":[\"TLR: TRL 2 may limit near-term value\",\"Sci-chemistry risk: CB1 inhibitors have natl safety concerns (psychoactive/side effects)\",\"IP position unclear; freedom-to-operate may be needed\",\"competition from existing CB1 inhibitors or peripheral selective approaches\"],\"one_sentence_take\":\"Moderate novelty and impact with early-stage readiness; significant risk from safety profile and early development stage, with room for scalable platform but requires IP/FOA validation.\"}","lead_inventor_name":"Beibei Chen","lead_inventor_dept":"Med-Medicine","technology_type":"Therapeutic Modality","technology_subtype":"Small Molecule","therapeutic_areas":["Hepatology","Endocrinology and Metabolic Diseases"],"therapeutic_indications":["Non-alcoholic steatohepatitis (NASH)","Cirrhosis","Obesity"],"custom_tags":[],"all_tech_innovators":["Beibei Chen","Toren Finkel","Yuan Liu"],"date_submitted":"2020-10-06","technology_readiness_level":"2. Initial proof of concept, in-vitro"},"highlight":{},"matched_queries":null,"score":0.0}